An in-depth analysis of ER+ breast cancer, focusing on its prevalence, molecular biology, current treatments, and emerging ...
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...
PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...
New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback